Lantern Pharma Inc. Payments to Acquire Marketable Securities
Lantern Pharma Inc. (LTRN) reported Payments to Acquire Marketable Securities of $14.72 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-14
- Lantern Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $4.20M.
- Lantern Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $2.08M, a 33.36% decline year-over-year.
- Lantern Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $3.46M, a 58.59% decline year-over-year.
- Lantern Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $4.98M, a 17.11% decline year-over-year.
- Lantern Pharma Inc. payments to acquire marketable securities for fiscal 2025 was $14.72M, a 14.78% decline from fiscal 2024.
- Lantern Pharma Inc. payments to acquire marketable securities for fiscal 2024 was $17.28M, a 110.78% increase from fiscal 2023.
- Lantern Pharma Inc. payments to acquire marketable securities for fiscal 2023 was $8.20M, a 109.48% increase from fiscal 2022.
- Lantern Pharma Inc. payments to acquire marketable securities for fiscal 2022 was $3.91M, a 80.02% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.28M derived: sum of 2 quarters · filed 2026-03-30 | $9.74M derived: sum of 3 quarters · filed 2026-08-14 | $14.72M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.53M derived: sum of 2 quarters · filed 2026-08-14 | $10.52M 10-Q · filed 2025-11-12 | $10.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $8.44M 10-Q · filed 2026-08-14 | $8.24M derived: sum of 3 quarters · filed 2026-08-14 | $11.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.98M 10-Q · filed 2026-05-15 | $4.78M derived: sum of 2 quarters · filed 2026-05-15 | $7.90M derived: sum of 3 quarters · filed 2026-05-15 | $16.25M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$201.03K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.92M derived: sum of 2 quarters · filed 2026-03-30 | $11.26M derived: sum of 3 quarters · filed 2026-03-30 | $17.28M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.46M derived: sum of 2 quarters · filed 2025-11-12 | $17.48M 10-Q · filed 2025-11-12 | $19.03M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $14.36M 10-Q · filed 2025-08-13 | $15.92M derived: sum of 3 quarters · filed 2025-08-13 | $16.65M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $6.01M 10-Q · filed 2025-05-15 | $7.57M derived: sum of 2 quarters · filed 2025-05-15 | $8.30M derived: sum of 3 quarters · filed 2025-05-15 | $11.11M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.29M derived: sum of 2 quarters · filed 2025-03-27 | $5.09M derived: sum of 3 quarters · filed 2025-03-27 | $8.20M 10-K · filed 2025-03-27 |
| 2023-09-30 | $731.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.54M derived: sum of 2 quarters · filed 2024-11-07 | $6.64M 10-Q · filed 2024-11-07 | $7.23M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.91M 10-Q · filed 2024-08-08 | $6.50M derived: sum of 3 quarters · filed 2024-08-08 | $7.82M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.10M 10-Q · filed 2024-05-09 | $3.69M derived: sum of 2 quarters · filed 2024-05-09 | $5.01M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $590.18K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.91M derived: sum of 2 quarters · filed 2024-03-18 | $3.91M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.32M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $2.00M 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $298.05K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.30M derived: sum of 2 quarters · filed 2023-03-20 | $19.58M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $999.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $19.28M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $18.28M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |